Core Viewpoint - Bixing Wulian's performance has drastically changed post-IPO, raising questions about the authenticity of its financial data and potential irregularities surrounding its listing [1][2][4] Group 1: Performance and Financial Data - Bixing Wulian reported a revenue of 329 million yuan in 2024, a decrease of 5.91% year-on-year, and a net loss of 38.54 million yuan, a decline of 264.92% [2] - The company experienced a significant performance drop after its IPO, with a net loss of 10.22 million yuan in Q1 2024, a decrease of 443.46% year-on-year [2] - The company has faced continuous regulatory inquiries since its listing, indicating concerns about the authenticity of its financial data [2][4] Group 2: IPO and Valuation Concerns - Bixing Wulian's IPO was marked by a significant valuation increase, with a registered capital increase from 53 million yuan to 58.89 million yuan, raising its valuation to approximately 900 million yuan [9][10] - The company’s financial performance prior to its IPO showed substantial growth, with revenue growth rates of 13.52% and 40.3% in 2020 and 2021, respectively [4] - There are discrepancies between Bixing Wulian's reported data and that of its industry peers, raising questions about the accuracy of its financial disclosures [7] Group 3: Customer Relationships and Transactions - Shanghai Koze became Bixing Wulian's largest customer in 2022, contributing 57.69 million yuan in sales, which accounted for 12.21% of total revenue [18] - There are concerns regarding the high performance bond ratios in contracts with Shanghai Koze, which exceed standard industry practices [24][25] - Bixing Wulian's relationship with former employees who now work for Shanghai Koze raises potential conflicts of interest and questions about the legitimacy of business dealings [20][21] Group 4: Regulatory and Compliance Issues - The company has faced criticism from regulators for its slow project progress and failure to disclose significant contracts in a timely manner [30] - Bixing Wulian's core investment projects have seen minimal progress, with completion rates of 0% and 6.57% for key initiatives as of the end of 2024 [30] - The company has been subject to public criticism and regulatory scrutiny due to its financial practices and governance issues [30]

Core Viewpoint - Qinghai Spring (600381.SH) is facing a delisting risk due to financial indicators triggering delisting clauses, with a warning of "ST" (Special Treatment) to be implemented after the 2024 annual report disclosure [1][2]. Financial Performance - The company expects a net profit loss attributable to shareholders of between 187 million to 225 million yuan for 2024, with a revenue forecast of approximately 256 million to 285 million yuan [2]. - The revenue has been revised down from an initial forecast of 310 million to 339 million yuan to below 300 million yuan, which is critical as it is below the 300 million yuan threshold that could trigger delisting [3][4]. Audit and Regulatory Concerns - The initial financial forecast was questioned by the Shanghai Stock Exchange, leading to an inquiry regarding the authenticity of revenue and the nature of business income [4]. - The auditing firm has raised doubts about the credibility of Qinghai Spring's financial statements, indicating potential for a disclaimer or adverse opinion on the 2024 financial report if sufficient audit evidence cannot be obtained [4][5]. Sales and Revenue Issues - Concerns have been raised regarding the sales of Cordyceps, with reported sales of approximately 152 million yuan, but significant accounts receivable of 56.87 million yuan, suggesting issues with the sales model [5]. - The white liquor segment showed abnormal revenue growth in December, accounting for about 50% of annual sales, which is deemed lacking commercial rationale given the overall market conditions [6][7]. Customer Transactions and Revenue Recognition - The company has been scrutinized for recognizing sales revenue from customers who have not yet sold the products, raising questions about the legitimacy of reported sales figures [7][8]. - Specific customers, such as Chengdu Tinghua Ling, reported significant sales but had not achieved corresponding sales post-delivery, indicating potential revenue recognition issues [9][10]. Conclusion - The discrepancies in reported sales figures and the ongoing audit concerns suggest that the financial health of Qinghai Spring is under significant scrutiny, with the upcoming annual report expected to provide further clarity on these issues [12].